Log in
Enquire now
‌

US Patent 10195281 Antibody formulations and uses thereof

Patent 10195281 was granted and assigned to Tracon Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Tracon Pharmaceuticals
Tracon Pharmaceuticals
0
Current Assignee
Tracon Pharmaceuticals
Tracon Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
101952810
Patent Inventor Names
Suzanne Benedict0
Charles Theuer0
Mark Cornell Manning0
Sharon Real0
Brian M. Murphy0
Date of Patent
February 5, 2019
0
Patent Application Number
144211080
Date Filed
September 5, 2013
0
Patent Primary Examiner
‌
Yunsoo Kim
0
Patent abstract

The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10195281 Antibody formulations and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.